Cover Image

Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy

Oral tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) family have been introduced into the clinic to treat human malignancies for decades. Despite superior properties of EGFR-TKIs as small molecule targeted drugs, their applications are still restricted due to their...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaohan Zhou (Author), Kun Shi (Author), Ying Hao (Author), Chengli Yang (Author), Ruoyu Zha (Author), Cheng Yi (Author), Zhiyong Qian (Author)
Format:	Book
Published:	Elsevier, 2020-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
by: Panupong Mahalapbutr, et al.
Published: (2024)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
by: Jing Zhu, et al.
Published: (2021)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy
by: Priyanka S. Waghmare, et al.
Published: (2024)

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
by: Haiyan Xu, et al.
Published: (2022)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
by: Cornelius Hempel, et al.
Published: (2017)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023)

Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017)

Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
by: Zahra Moradpour, et al.
Published: (2019)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
by: Tim Fischer, et al.
Published: (2018)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
by: Harpinder K. Brar, et al.
Published: (2022)

Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
by: O. O. Kovalov, et al.
Published: (2024)

4-Aryl-N-phenylpyrimidin-2-amines targeting EGFR-tyrosine kinase attenuated EGFR-expressing cell lines
by: Lueacha Tabtimmai, et al.
Published: (2022)

Targeting <i>BRAF</i> Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
by: Frank Aboubakar Nana, et al.
Published: (2021)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018)

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
by: Ou SH, et al.
Published: (2015)

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
by: Chao-Ju Chen, et al.
Published: (2021)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011)

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
by: Kun Wang, et al.
Published: (2021)

Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy
by: Josef Jampilek, et al.
Published: (2022)

Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells
by: Yuelong Jiang, et al.
Published: (2022)

Correction to: Fischer et al., Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
Published: (2018)

Transport of six tyrosine kinase inhibitors: active or passive?
by: Richard J. Honeywell, et al.
Published: (2016)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
by: Domenico Ribatti
Published: (2010)

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
by: Michael Menzel, et al.
Published: (2024)

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
by: Guangjian Yang, et al.
Published: (2022)

The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain
by: Delvenne Philippe, et al.
Published: (2011)

Subcellular localization of several structurally different tyrosine kinase inhibitors
by: Richard Honeywell, et al.
Published: (2018)

Pharmacovigilance study of tyrosine kinase inhibitors: Analysis of adverse reactions
by: Antoan Rangelov, et al.
Published: (2024)

Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies
by: Made Putra Semadhi, et al.
Published: (2017)

Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery
by: Sukanta Satapathy, et al.
Published: (2022)

miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
by: Yi-Nan Liu, et al.
Published: (2020)

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond
by: Yu Zhou, et al.
Published: (2024)